CHMP delivers negative opinion on duloxetine in fibromyalgia
This article was originally published in Scrip
The EU's CHMPhas adopted a negative opinion on extending the indications forLilly/Boehringer Ingelheim's antidepressant duloxetine (Cymbalta/Xeristar) 30mg and 60mg tablets to include the treatment of fibromyalgia. In contrast the US FDA approved the additional indication in June (Scrip Online, June 17th, 2008).
You may also be interested in...
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.